

# Virulence Factor and Biofilm Formation in Clinical Enterococcal Isolates of the West of Iran

Mahsa Kashef,<sup>1,2</sup> Amirhooshang Alvandi,<sup>1</sup> Banafshe Hasanvand,<sup>1,2</sup> Mohsen Azizi,<sup>1,2</sup> and Ramin Abiri<sup>1\*</sup>

<sup>1</sup>Microbiology Department, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

<sup>2</sup>Students Research Committee, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

\*Corresponding author: Ramin Abiri, Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Shirudi Blvd., Parastar Blvd, Kermanshah, Iran. Tel: +98-9122273648, Fax: +98-8334274623, E-mail: rabiri@kums.ac.ir

Received 2016 November 04; Revised 2017 April 18; Accepted 2017 May 17.

## Abstract

**Background:** *Enterococcus* spp., a part of the normal flora of the human intestine, possess several virulence factors that can develop biofilms to endure harsh environments. Their ability to cause nosocomial infections makes them as critical opportunistic pathogens in hospital settings.

**Objectives:** The current study aimed at determining the occurrence of 6 genes coding virulence factors and their ability to develop biofilms, and conducting phenotypical assessments of haemolysin and gelatinase in clinical enterococci isolated from the West of Iran.

**Methods:** A total of 126 isolates were screened for harbouring the following genes: aggregation substance (*asa1*), cytolysin (*cylABM*), enterococcal surface protein (*esp*), and gelatinase (*gelE*). Isolates were tested for haemolysin and gelatinase expression phenotypically and for biofilm production quantitatively, using the microtiter method.

**Results:** Of the 126 tested isolates, 95 (73%) were *Enterococcus faecalis* and 28 (21%) were *E. faecium*. The total frequency of virulence gene was *cylA* 92 (73%), *cylB* 85 (67%), *cylM* 57 (45%), *asa1* 26 (21%), *gelE* 64 (51%), and *esp* 66 (53%); while 98 (75%) of the isolates were able to form biofilm. A total of 74 (58%) and 46 (35%) isolates could secrete haemolysin and gelatinase.

**Conclusions:** There was a significant difference between the frequency of virulence gene in *E. faecalis* and *E. faecium*. *Enterococcus faecium* isolates lacked the *gelE* and *asa1* genes and the frequency of *cylABM* genes were lower than that of *E. faecalis* isolates. *Enterococcus faecalis* isolates were relatively rich in virulence factors; no association was observed between biofilm formation and the presence of specific virulence genes.

**Keywords:** Virulence Factor, Biofilm, *Enterococcus Faecalis*, *Enterococcus Faecium*

## 1. Background

Enterococci spp. are Gram-positive and catalase negative cocci, able to grow in the temperature range of 10°C to 45°C and media containing 6.5% NaCl (1). Enterococci are the second or third most prevalent organism responsible for nosocomial infections (2). Among the 50 identified species, *Enterococcus faecium* and *E. faecalis* are the most medically significant ones. *Enterococcus faecalis* is the most predominant species in hospital settings and accounts for 80% to 90% of nosocomial infections, compared to *E. faecium*, which causes 1% to 5% of such infections (3, 4). Enterococcal infections commonly occur in patients hospitalised for long periods and patients with severe chronic diseases such as renal failure, neutropenia, transplantation, and catheterisation. Important infections caused by enterococci are urinary tract infections (UTIs), bacteraemia, endocarditis, intra-abdominal and pelvic disease, and wound infections (2).

Enterococci are equipped with many genes encoding virulence factors that enable them to survive in harsh envi-

ronments and sustain infection in vulnerable hosts. Some virulence factors such as cytolysin (*cylA*, *cylB* and *cylM*), gelatinase (*gelE*), and aggregation substances (*asa1*) might increase the severity of the infections (5). Cytolysin is the main virulence factor of *E. faecalis*. The toxin is associated with increased pathogenicity of enterococcal infections in bacteraemia, endocarditis, and intraperitoneal infections (6). Cytolysin, as a lantibiotic, can target and lyse bacterial and mammalian cells (7-10). Nucleotide sequence determination for the cytolysin operon revealed a complex determinant encoding 5 genetic markers, of which *cylA*, *cylB*, and *cylM* are the most important ones (11, 12).

Observation of enterococcal biofilms on endodontic surfaces, biliary duct stents, urinary catheters, heart valves, and tissue surfaces suggested a correlation between the lifestyle and virulence (13). Biofilm formation is reportedly less common in *E. faecium* compared to *E. faecalis*, although the clinical outcome of infections caused by *E. faecium* may be worsening as a result of biofilm formation (14, 15). Biofilm production has profound effects on the devel-

opment of endocarditis, periodontitis, and various device-related infections, and also causes resistance to antibiotics (16, 17).

Enterococcal surface protein (Esp) may induce persistent UTIs and increase the ability of microorganisms to colonise in hospitalised patients (18, 19). The corresponding gene, *esp*, is more frequent in clinical *E. faecalis* and *E. faecium* isolates, compared to environmental or food product ones (20, 21). The *esp* expression is related to the primary bacterial adherence and biofilm formation (22, 23). Gelatinase encoded by *gelE* gene is an extracellular zinc metalloprotease that hydrolyses gelatine, collagen, casein, haemoglobin, and antimicrobial peptides of the innate immune system (24, 25). The *asai* is encoded by pheromone-responsive plasmids, which often harbour antibiotic resistance genes (26, 27). The protein causes clumping of *E. faecalis* cells and survival inside polymorphonuclear leucocytes, internalisation by intestinal cells, and increases in bacterial binding to cultured renal epithelial cells (28, 29).

## 2. Objectives

Considering the importance of bacterial virulence factors in the outcome of infections and lack of any comprehensive information about the prevalence of such factors in clinical isolates of enterococci in Iran, the current study aimed at investigating a possible relationship between the biofilm formation ability and virulence factors of enterococci isolated from clinical samples of an educational hospital in Kermanshah province, West of Iran, and also the role of virulence genes in biofilm development, and their prevalence especially as high-biofilm-producing isolates.

## 3. Methods

### 3.1. Bacterial Isolation and Identification

Among 130 suspicious clinical samples collected from January 2012 to April 2013, a total of 126 isolates were selected for the current study; samples were taken mostly from urine, blood, and body fluids samples. All samples were cultured on bile esculin agar (Himedia, India); positive cultures (colonies with a black halo around them) were confirmed at the species level using the standard biochemical methods.

### 3.2. Hemolysin Production

Haemolysin activity was determined by an overnight incubation of the isolates cultured on blood agar (Himedia, India) supplemented with 5% defibrinated human blood. A clear zone around the colonies indicated haemolysis.

### 3.3. Gelatinase Production

A pure 24-hour culture was stabbed into tubes containing a 0.8% nutrient broth (Himedia, India) supplemented with 12% gelatine. After 24 to 72 hours of incubation, tubes were refrigerated for 30 minutes. Sufficient gelatinase production by the isolates leads to liquefaction of cultured media, even following the refrigeration; but the presence of intact gelatine after refrigeration means a lack of ability to produce gelatinase.

### 3.4. Biofilm Formation Assay

The test was conducted using the previously described method (30). An overnight culture was diluted 1:100 into a fresh tryptic soy broth (TSB) medium (Himedia, India) supplemented with 1% glucose and inoculated into 96 polystyrene microplate wells. Following 18 hours of incubation at 37°C, the plates were gently washed 3 times with phosphate-buffered saline (PBS), air dried, and stained with crystal violet. Biofilm bounded to crystal violet was diluted with 200  $\mu$ L of an 80:20 mixture of ethanol and acetone and, then, optical density (OD) of the suspension was measured at 570 nm, using an automatic spectrophotometer (Stat Fax<sup>®</sup> 4200). The ability to form biofilm was scored as follows:  $OD \leq 0.120$ : non-producers,  $0.120 \leq OD < 0.240$ : weak producers, and  $OD \geq 0.240$ : strong producers. As a control, the level of crystal violet binding to wells was measured for the wells exposed only to the medium without bacteria. All biofilm assays were performed in triplicate (31).

### 3.5. DNA Extraction

A loopful of pure enterococci culture on brain-heart infusion (BHI) agar (Himedia, India) was suspended in microtubes containing 0.5 mL sterile deionised water. The microtubes were placed in a boiling water bath for 5 minutes, centrifuged for 10 minutes at 10000 rpm, and the supernatant were transferred to new tubes and used as DNA templates for the polymerase chain reaction (PCR).

### 3.6. Primer Design and PCR

The whole sequence of the enterococcus genome ID number: 427183854, retrieved from the NCBI database, was used as the template. On the basis of the retrieved sequence, 3 sets of primers were designed for *E. faecalis* and *E. faecium* *ddl* genes, which were strain-specific genes and enterococcus *tuf* gene, a genus-specific gene. Then, 6 sets of primers were designed for *asai*, *esp*, *gelE*, and *cylABM*. To optimise the results, the multiplex PCR reaction for 2 separate sets of genes was designed and performed. Enterococcal *Tuf* gene, *E. faecalis* and *E. faecium* *ddl* genes, *gelE*, and *esp* genes were placed in a set; *cylMBA* and *asai* were placed

in another set, separately. The primer sequences were summarized in [Table 1](#).

Multiplex PCR reactions were performed with the thermal cycler (Biorad, USA). The oligonucleotides for PCR amplification were purchased from Takapouzist Biotech Company (Iran). Reactions were performed in a total volume of 25  $\mu$ L, using 0.75 pmol of each of the 4 primer sets, 7.5  $\mu$ L 5X buffer, 50 mM MgCl<sub>2</sub>, 0.50  $\mu$ L dNTP 10 mM, and 1 U HStaq DNA polymerase (Kappa Biosystem USA). The amplification conditions were as follows: an initial denaturation step at 95°C for 1 minute; 34 cycles of denaturation at 95°C for 10 seconds; annealing at 55°C for 30 seconds for *gelE*, *esp*, enterococcus *tuf*, *E. faecalis ddl*, and *E. faecium ddl*; annealing at 52°C for 30 seconds for *cylA*, *cylB*, *cylM*, and *asa1*, and extension at 72°C for 1 minute, followed by the final extension at 72°C for 30 seconds. DNA from *E. faecalis* FI9190 was used as a positive control in the corresponding PCR reactions.

The PCR products were subjected to electrophoresis through 1% agarose gel, stained with ethidium bromide solution, and visualised under the UV light in the Gel Documentation system (Biorad, USA). Images were analysed using Image Lab software version 2.0.

### 3.7. Statistical Analysis

All statistical analyses were performed using SPSS version 21. Crosstabs, Chi-square, and the Fischer exact test were performed based on the data. A P value of < 0.05 was considered statistically significant.

## 4. Results

### 4.1. Bacterial Isolates Origin

Of the 126 clinical samples, 78 (60%) were isolated from urine, 30 (23%) and 22 (17%) from blood and body fluids samples, respectively; 95 (73%) isolates were *E. faecalis* and 28 (21%) *E. faecium*.

### 4.2. Frequency of Extracellular Enzyme Secretion

In the current study, 74 (58%) isolates were haemolysin producers, of which 51(68%) of *E. faecalis* and 20 (71%) of *E. faecium* isolates showed haemolytic activity. Alpha haemolytic strains were 26% of *E. faecalis* and 32% of *E. faecium* isolates, while beta haemolytic strains were 27% of *E. faecalis* and 39% of *E. faecium*. The results showed that 46 (35%) *E. faecalis* isolates could produce gelatinase. None of the *E. faecium* could liquefy gelatine; therefore, 49.3% of the *E. faecalis* isolates harbouring *gelE* did not show gelatinase activity.

### 4.3. Capacity for Biofilm Formation

Overall, 98 (75%) of the isolates could form biofilm, of which 75 (76%) and 23 (24%) were *E. faecalis* and *E. faecium*, respectively.

### 4.4. Distribution of Biofilm Production Capacity Among Virulence Marker

As many as 61 (92%) of all *esp*<sup>+</sup> and 64 (87%) of isolates that carried *gelE* gene could produce biofilm. Biofilm producers were 55 out of 64 *gelE*<sup>+</sup>, and 51 out of 64 *gelE*<sup>-</sup> isolates; the mean biofilm ODs for *gelE*<sup>+</sup> was more than that of *gelE*<sup>-</sup> isolates (2.033 versus 1.746) ([Table 2](#)). This trend was observed in the *esp*-lacking isolates, the mean biofilm OD of *gelE*<sup>+</sup> isolates was higher than that of *gelE*<sup>-</sup> ones, but the difference was not significant (mean OD, 1.747 for 24 *esp*<sup>+</sup>/*gelE*<sup>+</sup> isolates versus 1.392 for 31 *esp*<sup>+</sup>/*gelE*<sup>-</sup> isolates), which suggested a possible contribution of the *gelE* in biofilm formation in the *esp*-lacking isolates ([Table 2](#)). It was also noted that biofilm ODs were higher in 40 *esp*<sup>+</sup>/*gelE*<sup>+</sup> isolates (mean OD = 2.319). Moreover, the lowest mean of OD for the 31 *esp*<sup>+</sup>/*gelE*<sup>-</sup> isolates (mean OD = 1.392) showed that *esp*<sup>+</sup> isolates produced more biofilm than the *esp*<sup>-</sup> ones. A total of 26 *esp*<sup>+</sup>/*gelE*<sup>-</sup> isolates (mean OD= 2.103) also produced high amounts of biofilm, but a little less than *esp*<sup>+</sup>/*gelE*<sup>+</sup> (mean OD = 2.319). This could constitute strong evidence for the role of *esp* in biofilm formation in the absence of the *gelE* ([Table 2](#)).

However, even among the *esp*-lacking/*gelE*<sup>-</sup> isolates, 14 isolates produced strong biofilm and 8 isolates produced medium biofilm. Further, no significant difference was observed in the mean value of biofilm between the *esp*<sup>+</sup> and *esp*<sup>-</sup> isolates (ODs 1.569 vs. 2.211), indicating that neither *esp* nor *gelE* was essential to biofilm production. The relationship between biofilm formation capacities, OD values, *esp*, and *gelE* are summarised in [Table 2](#).

### 4.5. Frequency of Virulence Genes

The number of virulence marker genes in *E. faecalis* isolates varied from 1 to 6. The majority of *E. faecalis* isolates were positive for 4 virulence genes, but most of *E. faecium* isolates were positive for 3 virulence genes ([Table 3](#)). Of the 95 *E. faecalis* isolates, 10 (9.7%) were positive for 6 virulence genes, whereas 90 (91.9%) were positive for 2 or more virulence genes. None of *E. faecium* isolates was positive for *cylABM*, while 46 (48%) of *E. faecalis* strains harboured a *cylABM* complete set of genes. Among *E. faecalis* and *E. faecium* isolates, the *cylM* gene had a significantly lower incidence ([Table 3](#)).

The amplification results of enterococcal *tuf* gene, *E. faecalis*, and *E. faecium ddl* genes, *gelE*, and *esp* genes are illustrated in [Figure 1A](#) and those of *cylMBA* and *asa1* in [Figure 1B](#).

**Table 1.** Designed Primers Sequences

Primer Name	Virulence Factor	Oligonucleotide Sequence (5' to 3')	Amplicon Size, bp	Reference
<i>E. faecium</i> F	<i>Faecium</i> species	GAAGGACAATGGGTCAAAGG	596	The current study
<i>E. faecium</i> R		ACT TCG CCA GGC AAA GTC		
<i>Enterococcus</i> spp. F	<i>Enterococcus</i> genus	TAC TGA CAA ACC ATT CAT GAT G	109	The current study
<i>Enterococcus</i> spp. R		TTC GTC ACC AAC GCG AAC		
<i>E. faecalis</i> ddl F	<i>faecalis</i> species	CCA CAA GTA CCA TTC GTG C	305	The current study
<i>E. faecalis</i> ddl R		GCG ACA TCT TTC ACC ACT TC		
<i>esp</i> F	Enterococcal surface protein	GGT ATG GGT TCA ATC ACT GAC	714	The current study
<i>esp</i> R		CTC TGC ATC TTC AGG TAA G		
<i>gelE</i> F	Gelatinase	GAC CAG AAC AGA TTC ACT TG	409	The current study
<i>gelE</i> R		GGA TAC TCA GAG TGT TGA CC		
<i>cylM</i> F	Cytolysin	AGG GAG ACT CTC ATA GTC G	801	The current study
<i>cylM</i> R		CAG CAT ATC TTT GAG TTG GTC		
<i>cylA</i> F		GAT ATA ATA AAC GTG AGT CTT GG	238	The current study
<i>cylA</i> R		AGT CAG CAA TAT CAC CAC TC		
<i>cylB</i> F		CTG GCT GGA TTG TTA CAA CC	526	The current study
<i>cylB</i> R		GAT CTT CAT GCT TTC CAA TAC		
<i>asaI</i> F	Aggregation substance	CAA GAA CAA CCA GTA GTA AGC	960	The current study
<i>asaI</i> R		TGA ATT TAA TGA AGC ACC TG		

**Table 2.** Biofilm Formation Quantity Based on the Presence of *esp/gelE* Gene

Virulence Factor	OD of Isolates with				Mean $\pm$ SD, P value
	Strong Biofilm Formation, (OD <sub>570</sub> $\leq$ 2)	Medium Biofilm Formation, (OD <sub>570</sub> , 1-2)	Weak Biofilm Formation, (0.5 $\leq$ OD <sub>570</sub> $\geq$ 1)	No Biofilm Formation, (OD <sub>570</sub> $\leq$ 0.5)	
<i>Esp</i> <sup>+</sup> / <i>gelE</i> <sup>+</sup>	2.419 (2.783 - 2.132) (34)	1.284, (1.074 - 1.494) (2)	0.883 (2)	0.204 (1)	2.319 (2.783 - 0.204) (40) (0.57) 0.053
<i>Esp</i> <sup>+</sup> / <i>gelE</i> <sup>-</sup>	2.650 (2.947 - 2.048) (17)	1.618 (1.855 - 1.154) (6)	0.783 (0.652 - 0.914) (2)	0.209 (1)	2.103 (2.813 - 0.209) (26) (0.79) 0.263
<i>esp</i> <sup>-</sup> / <i>gelE</i> <sup>+</sup>	2.440 (2.674 - 2.190) (8)	1.516 (1.988 - 1.108) (12)	0.756 (0.658 - 0.854) (2)	0.115 (0.121 - 0.111) (2)	1.206 (2.718 - 0.111) (24) (0.76) 0.925
<i>esp</i> <sup>-</sup> / <i>gelE</i> <sup>-</sup>	2.611 (2.993 - 2.000) (14)	1.461 (1.986 - 1.005) (8)	0.595 (0.661 - 0.579) (8)	0.028 (0.025 - 0.031) (7)	1.392 (2.993 - 0.025) (31) (0.94) 0.196
Total	73	28	14	11	126

**Table 3.** Frequency of Virulence Genes<sup>a</sup>

Variables	<i>cylA</i>	<i>cylB</i>	<i>CylM</i>	<i>cylABM</i>	<i>AsaI</i>	<i>cylABM, asaI</i>	<i>gelE</i>	<i>esp</i>	<i>gelE, esp</i>
<i>E. faecalis</i>	83 (87)	77 (81.1)	52 (54.4)	46 (59)	26 (27)	17 (36)	64 (67)	55 (59)	52 (41)
<i>E. faecium</i>	9 (32)	8 (28)	5 (17)	0	0	0	0	11 (40)	0
Total (126)	92 (73)	85 (67)	57 (45)	46 (37)	26 (21)	(14.38)	64 (51)	66 (53)	41 (33)

<sup>a</sup>Values are expressed as No. (%).


## 5. Discussion

*Enterococcus* is among the 4 most common causes of nosocomial infections worldwide. Due to its intrinsic resistance to antimicrobial agents and harsh environments, it can survive and spread in hostile niches, such as hospitals. In enterococcal infections, biofilm plays an essential role by providing a context to enhance microbial survival in the host (32-34). Several studies were conducted to identify the virulence factors of enterococci and their possible association with biofilm formation, but this issue is not yet well understood. To reduce the rate of nosocomial infec-

tions and implement the correct treatment strategies, it is vital to obtain reliable knowledge on bacterial capacities and their virulence factors (17, 32, 33, 35-39).

The current study aimed at evaluating the frequency of several virulence factors in clinical enterococcal isolates and their relationship with biofilm production. Therefore, a multiplex PCR was designed to simultaneously detect *tuf* (*Enterococcus* genus), *ddl* (*E. faecalis* species), *ddl* (*E. faecium* species), *gelE* (gelatinase), *esp*, *cylA*, *cylB*, *cylM* (cytolysin), and *asaI*. All 126 isolates were analysed for the presence of virulence genes by the researcher-designed primers. The

Figure 1. Figure 1



A, From left to right: Lane 1, Sinacolon 100 bp DNA marker; Lane 2, Positive control of 109, 305, 409, and 714 bp of targeted genes; Lane 3, Negative control; Lane 4 - 13, Electrophoresis of PCR products. B, From left to right: Lane 1, Sinaclon 100 bp DNA marker; Lane 2, Positive control of 238, 526, 801 and 960 bp of targeted gene; Lane 3, Negative control; Lane 4 - 12, Electrophoresis of PCR products.

results are presented in Table 3, which revealed a relatively high incidence of virulence factors among isolates. The frequencies of all 6 virulence factors were significantly high in *E. faecalis* than *E. faecium* (Table 3). Previous observations revealed a higher rate of clinical isolates harbouring *esp* compared to the isolates from other resources (19, 21).

In the present study, the prevalence of *esp* was consistent with those of other studies in Iran and other parts of the world, although some studies failed to find *esp*<sup>+</sup>*E. faecium* (18, 36, 40, 41). The Esp has a role in colonisation and persistence of *E. faecalis* in the urinary tract (18). Since most isolates in the current study were isolated from UTIs, a high incidence of *esp* was not surprising. The Esp protein has a high sequence similarity with Bap (biofilm-associated protein of *Staphylococcus aureus*); thus, this protein may be important for biofilm formation (42). Di Rosa suggested that the synergy between *esp* and biofilm formation helps to establish a successful infection (43). The current study also detected the ability of enterococcal isolates to form biofilms and their possible relationship with *esp*.

According to the literature, all enterococcal strains isolated from urinary and blood stream sources can produce biofilm, with a rate typically higher than that of the current study (30, 42, 44). Despite the lack of a significant association between Esp and biofilm formation in the current study, other researches reported conflicting results about the role of *E. faecalis* Esp in biofilm formation (23, 42, 43, 45-48). Although biofilm formation in *esp*-deficient mutants of *E. faecalis* was not reported in all studies, many others report no correlation between the presence of *esp* and

biofilm formation, which is a multifactorial process (49, 50).

Gelatinase, another virulence factor of *E. faecalis*, was also detected in the current study. The frequency of *gelE* was the same as those of previous studies (5, 44, 51), which also could not detect this gene in *E. faecium* isolates, although many *E. faecalis* isolates harboured it (52). Furthermore, phenotypical expression of *gelE*, which leads to the secretion of gelatinase, was assessed and many *gelE*<sup>+</sup>*E. faecalis* isolates failed to secrete gelatinase. A reason for the phenomenon could be that the presence of a specific gene does not automatically mean phenotypic expression of that gene. This could explain the presence of the *gelE*<sup>+</sup> isolates, which were unable to liquefy gelatine (53-56).

Despite demonstrations about the necessity of gelatinase enzymatic activity to establish biofilm (45), the current study found no difference in the *in vitro* biofilm production between *gelE*<sup>+</sup> and *gelE*<sup>-</sup> isolates; which indicated that, similar to *esp*, neither *gelE*, nor gelatinase was required for biofilm formation. In summary, although biofilm production was higher in *esp*<sup>+</sup>/*gelE*<sup>+</sup> compared to *esp*<sup>-</sup>/*gelE*<sup>-</sup> isolates, no significant difference was observed in biofilm production ability between *gelE*<sup>+</sup> and *gelE*<sup>-</sup> isolates. The *asa1* was not found in any of the *E. faecium* strains investigated in the current study. In other studies, *asa1* was detected only in *E. faecalis* strains (28, 44, 51, 54, 57). Udo reported a relatively similar frequency of *asa1*; Moniri and Seno reported a higher frequency (41, 58, 59).

Cytolysin can induce tissue damage through the lysis of erythrocytes and polymorphonuclears (PMNs) (60).

Cytolysin production could also significantly deteriorate the severity of endocarditis (7). Investigation of cytolysin genes revealed the presence of *cylA*, *cylB*, and *cylM* in a high proportion of *E. faecalis* and a low proportion of *E. faecium* isolates, but in the studies by Udo, Moniri, and Cosentino, the prevalence of *cylA*, *cylB*, and *cylM* were lower than those of the current study (41, 59, 61). However, Abriouel reported a higher frequency of *cyl* operon in *E. faecalis*, although with lower haemolytic activity (62).

*Enterococcus faecalis* isolates harboured 1 to 6 virulence markers, similar to a report by a Brazilian study in which *E. faecalis* isolates harboured 1 to 8 virulence-associated genes (63). The current study observed the dominance of some genes or gene combinations. The most common combinations of virulence genes were *cylA* and *cylB* (76%) for *E. faecalis*, and *cylM* and *cylA1* (12%) for *E. faecium* isolates. Among all *E. faecalis* isolates, 9 isolates had 6 virulence markers, all of which were strong biofilm producers.

All *E. faecalis* isolates harboured more than 1 virulence-associated gene, suggesting that *E. faecalis* infection depended upon the transaction of several genes bound to the secretion and regulation of the expression of the virulence factors. The small number of *E. faecium* isolates was the limitation of the current study. However, the current study reinforced the well-known characteristics of *E. faecalis* species in terms of its virulence, and confirmed that biofilm formation was a multifactorial process requiring different genes and their products.

### 5.1. Conclusion

In conclusion, *E. faecalis* strains isolated from UTIs were characterised by higher-virulence strains from other clinical sources. *Enterococcus faecium* was involved in important processes such as initiating colonisation, infection in the host, and biofilm formation. Overall, *esp* was not required for biofilm formation, but its presence was significantly associated with a higher proportion of biofilm production in clinical isolates. Therefore, the genotypic and phenotypic assays appear necessary for a better characterisation of the strains, due to silent virulence genes (*cyl* and *gelE*). The current study results may serve as a basis for the additional surveillance studies of infections caused by this microorganism.

### References

- Sherman JM. The Streptococci. *Bacteriol Rev.* 1937;1(1):3-97. [PubMed: 16350049].
- Jett BD, Huycke MM, Gilmore MS. Virulence of enterococci. *Clin Microbiol Rev.* 1994;7(4):462-78. doi: 10.1128/CMR.7.4.462. [PubMed: 7834601].
- Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. *Infect Control Hosp Epidemiol.* 2000;21(8):510-5. doi: 10.1086/501795. [PubMed: 10968716].
- Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. *Pediatr Infect Dis J.* 2003;22(8):686-91. doi: 10.1097/01.inf.0000078159.53132.40. [PubMed: 12913767].
- Elsner HA, Sobottka I, Mack D, Claussen M, Laufs R, Wirth R. Virulence factors of *Enterococcus faecalis* and *Enterococcus faecium* blood culture isolates. *Eur J Clin Microbiol Infect Dis.* 2000;19(1):39-42. [PubMed: 10706178].
- Singh KV, Qin X, Weinstock GM, Murray BE. Generation and testing of mutants of *Enterococcus faecalis* in a mouse peritonitis model. *J Infect Dis.* 1998;178(5):1416-20. doi: 10.1086/314453. [PubMed: 9780263].
- Chow JW, Thal LA, Perri MB, Vazquez JA, Donabedian SM, Clewell DB, et al. Plasmid-associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. *Antimicrob Agents Chemother.* 1993;37(11):2474-7. doi: 10.1128/AAC.37.11.2474. [PubMed: 8285637].
- Huycke MM, Spiegel CA, Gilmore MS. Bacteremia caused by hemolytic, high-level gentamicin-resistant *Enterococcus faecalis*. *Antimicrob Agents Chemother.* 1991;35(8):1626-34. doi: 10.1128/AAC.35.8.1626. [PubMed: 1929336].
- Ike Y, Hashimoto H, Clewell DB. Hemolysin of *Streptococcus faecalis* subspecies zymogenes contributes to virulence in mice. *Infect Immun.* 1984;45(2):528-30. [PubMed: 6086531].
- Jett BD, Jensen HG, Nordquist RE, Gilmore MS. Contribution of the pADI-encoded cytolysin to the severity of experimental *Enterococcus faecalis* endophthalmitis. *Infect Immun.* 1992;60(6):2445-52. [PubMed: 1587612].
- Booth MC, Bogie CP, Sahl HG, Siezen RJ, Hatter KL, Gilmore MS. Structural analysis and proteolytic activation of *Enterococcus faecalis* cytolysin, a novel lantibiotic. *Mol Microbiol.* 1996;21(6):1175-84. doi: 10.1046/j.1365-2958.1996.831449.x. [PubMed: 8898386].
- Sahl HG, Bierbaum G. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. *Annu Rev Microbiol.* 1998;52:41-79. doi: 10.1146/annurev.micro.52.1.41. [PubMed: 9891793].
- Carniol K, Gilmore MS. Signal transduction, quorum-sensing, and extracellular protease activity in *Enterococcus faecalis* biofilm formation. *J Bacteriol.* 2004;186(24):8161-3. doi: 10.1128/JB.186.24.8161-8163.2004. [PubMed: 15576763].
- Mohamed JA, Huang DB. Biofilm formation by enterococci. *J Med Microbiol.* 2007;56(Pt 12):1581-8. doi: 10.1099/jmm.0.47331-0. [PubMed: 18033823].
- Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev.* 2002;15(2):167-93. doi: 10.1128/CMR.15.2.167-193.2002. [PubMed: 11932229].
- O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. *Annu Rev Microbiol.* 2000;54:49-79. doi: 10.1146/annurev.micro.54.1.49. [PubMed: 11018124].
- Duggan JM, Sedgley CM. Biofilm formation of oral and endodontic *Enterococcus faecalis*. *J Endod.* 2007;33(7):815-8. doi: 10.1016/j.joen.2007.02.016. [PubMed: 17804318].
- Shankar N, Lockett CV, Baghdayan AS, Drachenberg C, Gilmore MS, Johnson DE. Role of *Enterococcus faecalis* surface protein *Esp* in the pathogenesis of ascending urinary tract infection. *Infect Immun.* 2001;69(7):4366-72. doi: 10.1128/IAI.69.7.4366-4372.2001. [PubMed: 11401975].
- Shankar V, Baghdayan AS, Huycke MM, Lindahl G, Gilmore MS. Infection-derived *Enterococcus faecalis* strains are enriched in *esp*, a gene encoding a novel surface protein. *Infect Immun.* 1999;67(1):193-200. [PubMed: 9864215].

20. Leavis H, Top J, Shankar N, Borgen K, Bonten M, van Embden J, et al. A novel putative enterococcal pathogenicity island linked to the esp virulence gene of *Enterococcus faecium* and associated with epidemicity. *J Bacteriol.* 2004;**186**(3):672–82. doi: [10.1128/JB.186.3.672-682.2004](https://doi.org/10.1128/JB.186.3.672-682.2004). [PubMed: [14729692](https://pubmed.ncbi.nlm.nih.gov/14729692/)].
21. Eaton TJ, Gasson MJ. A variant enterococcal surface protein Esp(fm) in *Enterococcus faecium*; distribution among food, commensal, medical, and environmental isolates. *FEMS Microbiol Lett.* 2002;**216**(2):269–75. doi: [10.1111/j.1574-6968.2002.tb11446.x](https://doi.org/10.1111/j.1574-6968.2002.tb11446.x). [PubMed: [12435513](https://pubmed.ncbi.nlm.nih.gov/12435513/)].
22. Heikens E, Bonten MJ, Willems RJ. Enterococcal surface protein Esp is important for biofilm formation of *Enterococcus faecium* E1162. *J Bacteriol.* 2007;**189**(22):8233–40. doi: [10.1128/JB.01205-07](https://doi.org/10.1128/JB.01205-07). [PubMed: [17827282](https://pubmed.ncbi.nlm.nih.gov/17827282/)].
23. Tendolkar PM, Baghdayan AS, Gilmore MS, Shankar N. Enterococcal surface protein, Esp, enhances biofilm formation by *Enterococcus faecalis*. *Infect Immun.* 2004;**72**(10):6032–9. doi: [10.1128/IAI.72.10.6032-6039.2004](https://doi.org/10.1128/IAI.72.10.6032-6039.2004). [PubMed: [15385507](https://pubmed.ncbi.nlm.nih.gov/15385507/)].
24. Nakayama J, Cao Y, Horii T, Sakuda S, Akkermans AD, de Vos WM, et al. Gelatinase biosynthesis-activating pheromone: a peptide lactone that mediates a quorum sensing in *Enterococcus faecalis*. *Mol Microbiol.* 2001;**41**(1):145–54. doi: [10.1046/j.1365-2958.2001.02486.x](https://doi.org/10.1046/j.1365-2958.2001.02486.x). [PubMed: [11454207](https://pubmed.ncbi.nlm.nih.gov/11454207/)].
25. Zeng J, Teng F, Murray BE. Gelatinase is important for translocation of *Enterococcus faecalis* across polarized human enterocyte-like T84 cells. *Infect Immun.* 2005;**73**(3):1606–12. doi: [10.1128/IAI.73.3.1606-1612.2005](https://doi.org/10.1128/IAI.73.3.1606-1612.2005). [PubMed: [15731060](https://pubmed.ncbi.nlm.nih.gov/15731060/)].
26. Sartingen S, Rozdzinski E, Muscholl-Silberhorn A, Marre R. Aggregation substance increases adherence and internalization, but not translocation, of *Enterococcus faecalis* through different intestinal epithelial cells in vitro. *Infect Immun.* 2000;**68**(10):6044–7. doi: [10.1128/IAI.68.10.6044-6047.2000](https://doi.org/10.1128/IAI.68.10.6044-6047.2000). [PubMed: [10992519](https://pubmed.ncbi.nlm.nih.gov/10992519/)].
27. Rozdzinski E, Marre R, Susa M, Wirth R, Muscholl-Silberhorn A. Aggregation substance-mediated adherence of *Enterococcus faecalis* to immobilized extracellular matrix proteins. *Microb Pathog.* 2001;**30**(4):211–20. doi: [10.1006/mpat.2000.0429](https://doi.org/10.1006/mpat.2000.0429). [PubMed: [11312614](https://pubmed.ncbi.nlm.nih.gov/11312614/)].
28. Sussmuth SD, Muscholl-Silberhorn A, Wirth R, Susa M, Marre R, Rozdzinski E. Aggregation substance promotes adherence, phagocytosis, and intracellular survival of *Enterococcus faecalis* within human macrophages and suppresses respiratory burst. *Infect Immun.* 2000;**68**(9):4900–6. doi: [10.1128/IAI.68.9.4900-4906.2000](https://doi.org/10.1128/IAI.68.9.4900-4906.2000). [PubMed: [10948103](https://pubmed.ncbi.nlm.nih.gov/10948103/)].
29. Isenmann R, Schwarz M, Rozdzinski E, Marre R, Beger HG. Aggregation substance promotes colonic mucosal invasion of *Enterococcus faecalis* in an ex vivo model. *J Surg Res.* 2000;**89**(2):132–8. doi: [10.1006/jsre.1999.5813](https://doi.org/10.1006/jsre.1999.5813). [PubMed: [10729241](https://pubmed.ncbi.nlm.nih.gov/10729241/)].
30. Baldassarri L, Bertuccini L, Ammendolia MG, Gherardi G, Creti R. Variant esp gene in vancomycin-sensitive *Enterococcus faecium*. *Lancet.* 2001;**357**(9270):1802. doi: [10.1016/S0140-6736\(00\)04919-9](https://doi.org/10.1016/S0140-6736(00)04919-9). [PubMed: [11407387](https://pubmed.ncbi.nlm.nih.gov/11407387/)].
31. Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I, et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. *APMIS.* 2007;**115**(8):891–9. doi: [10.1111/j.1600-0463.2007.apm\\_630.x](https://doi.org/10.1111/j.1600-0463.2007.apm_630.x). [PubMed: [17696944](https://pubmed.ncbi.nlm.nih.gov/17696944/)].
32. Lewis K. Riddle of biofilm resistance. *Antimicrob Agents Chemother.* 2001;**45**(4):999–1007. doi: [10.1128/AAC.45.4.999-1007.2001](https://doi.org/10.1128/AAC.45.4.999-1007.2001). [PubMed: [11257008](https://pubmed.ncbi.nlm.nih.gov/11257008/)].
33. Yasuda H, Ajiki Y, Aoyama J, Yokota T. Interaction between human polymorphonuclear leucocytes and bacteria released from in-vitro bacterial biofilm models. *J Med Microbiol.* 1994;**41**(5):359–67. doi: [10.1099/00222615-41-5-359](https://doi.org/10.1099/00222615-41-5-359). [PubMed: [7966209](https://pubmed.ncbi.nlm.nih.gov/7966209/)].
34. Azizi O, Shakibaie MR, Modarresi F, Shahcheraghi F. Molecular Detection of Class-D OXA Carbapenemase Genes in Biofilm and Non-Biofilm Forming Clinical Isolates of *Acinetobacter baumannii*. *Jundishapur J Microbiol.* 2015;**8**(1):e21042. doi: [10.5812/jjm.21042](https://doi.org/10.5812/jjm.21042). [PubMed: [25789134](https://pubmed.ncbi.nlm.nih.gov/25789134/)].
35. Baldassarri L, Creti R, Recchia S, Pataracchia M, Alfarone G, Orefici G, et al. Virulence factors in enterococcal infections of orthopedic devices. *Int J Artif Organs.* 2006;**29**(4):402–6. [PubMed: [16705609](https://pubmed.ncbi.nlm.nih.gov/16705609/)].
36. Sharifi Y, Hasani A, Ghotaslou R, Naghili B, Aghazadeh M, Milani M, et al. Virulence and antimicrobial resistance in enterococci isolated from urinary tract infections. *Adv Pharm Bull.* 2013;**3**(1):197–201. doi: [10.5681/apb.2013.032](https://doi.org/10.5681/apb.2013.032). [PubMed: [24312835](https://pubmed.ncbi.nlm.nih.gov/24312835/)].
37. Worth LJ, Slavin MA, Vankerckhoven V, Goossens H, Grabsch EA, Thursky KA. Virulence determinants in vancomycin-resistant *Enterococcus faecium* vanB: clonal distribution, prevalence and significance of esp and hyl in Australian patients with haematological disorders. *J Hosp Infect.* 2008;**68**(2):137–44. doi: [10.1016/j.jhin.2007.10.017](https://doi.org/10.1016/j.jhin.2007.10.017). [PubMed: [18079021](https://pubmed.ncbi.nlm.nih.gov/18079021/)].
38. Kayaoglu G, Orstavik D. Virulence factors of *Enterococcus faecalis*: relationship to endodontic disease. *Crit Rev Oral Biol Med.* 2004;**15**(5):308–20. [PubMed: [15470268](https://pubmed.ncbi.nlm.nih.gov/15470268/)].
39. Sedgley CM, Molander A, Flannagan SE, Nagel AC, Appelbe OK, Clewell DB, et al. Virulence, phenotype and genotype characteristics of endodontic *Enterococcus* spp. *Oral Microbiol Immunol.* 2005;**20**(1):10–9. doi: [10.1111/j.1399-302X.2004.00180.x](https://doi.org/10.1111/j.1399-302X.2004.00180.x). [PubMed: [15612939](https://pubmed.ncbi.nlm.nih.gov/15612939/)].
40. Nakayama J, Tanaka E, Kariyama R, Nagata K, Nishiguchi K, Mitsuhashi R, et al. Siamycin attenuates fsr quorum sensing mediated by a gelatinase biosynthesis-activating pheromone in *Enterococcus faecalis*. *J Bacteriol.* 2007;**189**(4):1358–65. doi: [10.1128/JB.00969-06](https://doi.org/10.1128/JB.00969-06). [PubMed: [17071762](https://pubmed.ncbi.nlm.nih.gov/17071762/)].
41. Moniri R, Ghasemi A, Moosavi SGA, Dastehgoli K, Rezaei M. Virulence gene's relationship with biofilm formation and detection of aac (6')aph (2") in enterococcus faecalis isolated from patients with urinary tract infection. *Jundishapur J Microbiol.* 2013;**6**(5) doi: [10.5812/jjm.6244](https://doi.org/10.5812/jjm.6244).
42. Toledo-Arana A, Valle J, Solano C, Arrizubieta MJ, Cucarella C, Lamata M, et al. The enterococcal surface protein, Esp, is involved in *Enterococcus faecalis* biofilm formation. *Appl Environ Microbiol.* 2001;**67**(10):4538–45. [PubMed: [11571153](https://pubmed.ncbi.nlm.nih.gov/11571153/)].
43. Di Rosa R, Creti R, Venditti M, D'Amelio R, Arciola CR, Montanaro L, et al. Relationship between biofilm formation, the enterococcal surface protein (Esp) and gelatinase in clinical isolates of *Enterococcus faecalis* and *Enterococcus faecium*. *FEMS Microbiol Lett.* 2006;**256**(1):145–50. doi: [10.1111/j.1574-6968.2006.00112.x](https://doi.org/10.1111/j.1574-6968.2006.00112.x). [PubMed: [16487332](https://pubmed.ncbi.nlm.nih.gov/16487332/)].
44. Dupre I, Zanetti S, Schito AM, Fadda G, Sechi LA. Incidence of virulence determinants in clinical *Enterococcus faecium* and *Enterococcus faecalis* isolates collected in Sardinia (Italy). *J Med Microbiol.* 2003;**52**(Pt 6):491–8. doi: [10.1099/jmm.0.05038-0](https://doi.org/10.1099/jmm.0.05038-0). [PubMed: [12748268](https://pubmed.ncbi.nlm.nih.gov/12748268/)].
45. Hancock LE, Perego M. Systematic inactivation and phenotypic characterization of two-component signal transduction systems of *Enterococcus faecalis* V583. *J Bacteriol.* 2004;**186**(23):7951–8. doi: [10.1128/JB.186.23.7951-7958.2004](https://doi.org/10.1128/JB.186.23.7951-7958.2004). [PubMed: [15547267](https://pubmed.ncbi.nlm.nih.gov/15547267/)].
46. Kristich CJ, Li YH, Cvitkovitch DG, Dunny GM. Esp-independent biofilm formation by *Enterococcus faecalis*. *J Bacteriol.* 2004;**186**(1):154–63. doi: [10.1128/JB.186.1.154-163.2004](https://doi.org/10.1128/JB.186.1.154-163.2004). [PubMed: [14679235](https://pubmed.ncbi.nlm.nih.gov/14679235/)].
47. Raad I, Hanna HA, Boktour M, Chaiban G, Hachem RY, Dvorak T, et al. Vancomycin-resistant *Enterococcus faecium*: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. *Antimicrob Agents Chemother.* 2005;**49**(12):5046–50. doi: [10.1128/AAC.49.12.5046-5050.2005](https://doi.org/10.1128/AAC.49.12.5046-5050.2005). [PubMed: [16304171](https://pubmed.ncbi.nlm.nih.gov/16304171/)].
48. Tendolkar PM, Baghdayan AS, Shankar N. The N-terminal domain of enterococcal surface protein, Esp, is sufficient for Esp-mediated biofilm enhancement in *Enterococcus faecalis*. *J Bacteriol.* 2005;**187**(17):6213–22. doi: [10.1128/JB.187.17.6213-6222.2005](https://doi.org/10.1128/JB.187.17.6213-6222.2005). [PubMed: [16109963](https://pubmed.ncbi.nlm.nih.gov/16109963/)].
49. Pultz NJ, Shankar N, Baghdayan AS, Donskey CJ. Enterococcal surface protein Esp does not facilitate intestinal colonization or translocation of *Enterococcus faecalis* in clindamycin-treated mice. *FEMS Microbiol Lett.* 2005;**242**(2):217–9. doi: [10.1016/j.femsle.2004.11.006](https://doi.org/10.1016/j.femsle.2004.11.006).

- [PubMed: 15621440].
50. Heikens E, Leendertse M, Wijnands LM, van Luit-Asbroek M, Bonten MJ, van der Poll T, et al. Enterococcal surface protein Esp is not essential for cell adhesion and intestinal colonization of *Enterococcus faecium* in mice. *BMC Microbiol.* 2009;**9**:19. doi: [10.1186/1471-2180-9-19](https://doi.org/10.1186/1471-2180-9-19). [PubMed: 19178704].
  51. Franz CM, Muscholl-Silberhorn AB, Yousif NM, Vancanneyt M, Swings J, Holzapfel WH. Incidence of virulence factors and antibiotic resistance among *Enterococci* isolated from food. *Appl Environ Microbiol.* 2001;**67**(9):4385-9. [PubMed: 11526054].
  52. Coque TM, Patterson JE, Steckelberg JM, Murray BE. Incidence of hemolysin, gelatinase, and aggregation substance among enterococci isolated from patients with endocarditis and other infections and from feces of hospitalized and community-based persons. *J Infect Dis.* 1995;**171**(5):1223-9. [PubMed: 7751697].
  53. Creti R, Imperi M, Bertuccini L, Fabretti F, Orefici G, Di Rosa R, et al. Survey for virulence determinants among *Enterococcus faecalis* isolated from different sources. *J Med Microbiol.* 2004;**53**(Pt 1):13-20. doi: [10.1099/jmm.0.05353-0](https://doi.org/10.1099/jmm.0.05353-0). [PubMed: 14663100].
  54. Eaton TJ, Gasson MJ. Molecular screening of *Enterococcus* virulence determinants and potential for genetic exchange between food and medical isolates. *Appl Environ Microbiol.* 2001;**67**(4):1628-35. doi: [10.1128/AEM.67.4.1628-1635.2001](https://doi.org/10.1128/AEM.67.4.1628-1635.2001). [PubMed: 11282615].
  55. Jurkovic D, Krizkova L, Dusinsky R, Belicova A, Sojka M, Krajcovic J, et al. Identification and characterization of enterococci from bryndza cheese. *Lett Appl Microbiol.* 2006;**42**(6):553-9. doi: [10.1111/j.1472-765X.2006.01918.x](https://doi.org/10.1111/j.1472-765X.2006.01918.x). [PubMed: 16706891].
  56. Tzikrikonis G, Maniatis AN, Labrou M, Ntokou E, Michail G, Daponte A, et al. Differences in biofilm formation and virulence factors between clinical and fecal enterococcal isolates of human and animal origin. *Microb Pathog.* 2012;**52**(6):336-43. doi: [10.1016/j.micpath.2012.03.003](https://doi.org/10.1016/j.micpath.2012.03.003). [PubMed: 22445820].
  57. Mannu L, Paba A, Daga E, Comunian R, Zanetti S, Dupre I, et al. Comparison of the incidence of virulence determinants and antibiotic resistance between *Enterococcus faecium* strains of dairy, animal and clinical origin. *Int J Food Microbiol.* 2003;**88**(2-3):291-304. doi: [10.1016/S0168-1605\(03\)00191-0](https://doi.org/10.1016/S0168-1605(03)00191-0). [PubMed: 14597001].
  58. Seno Y, Kariyama R, Mitsuhata R, Monden K, Kumon H. Clinical implications of biofilm formation by *Enterococcus faecalis* in the urinary tract. *Acta Med Okayama.* 2005;**59**(3):79-87. [PubMed: 16049560].
  59. Udo EE, Al-Sweih N. Frequency of virulence-associated genes in *Enterococcus faecalis* isolated in Kuwait hospitals. *Med Princ Pract.* 2011;**20**(3):259-64. doi: [10.1159/000321230](https://doi.org/10.1159/000321230). [PubMed: 21454997].
  60. Jett BD, Gilmore MS. The growth-inhibitory effect of the *Enterococcus faecalis* bacteriocin encoded by pAD1 extends to the oral streptococci. *J Dent Res.* 1990;**69**(10):1640-5. doi: [10.1177/00220345900690100301](https://doi.org/10.1177/00220345900690100301). [PubMed: 2120304].
  61. Cosentino S, Podda GS, Corda A, Fadda ME, Deplano M, Pisano MB. Molecular detection of virulence factors and antibiotic resistance pattern in clinical *Enterococcus faecalis* strains in Sardinia. *J Prev Med Hyg.* 2010;**51**(1):31-6. [PubMed: 20853674].
  62. Abriouel H, Omar NB, Molinos AC, Lopez RL, Grande MJ, Martinez-Viedma P, et al. Comparative analysis of genetic diversity and incidence of virulence factors and antibiotic resistance among enterococcal populations from raw fruit and vegetable foods, water and soil, and clinical samples. *Int J Food Microbiol.* 2008;**123**(1-2):38-49. doi: [10.1016/j.ijfoodmicro.2007.11.067](https://doi.org/10.1016/j.ijfoodmicro.2007.11.067). [PubMed: 18180067].
  63. Bittencourt de Marques E, Suzart S. Occurrence of virulence-associated genes in clinical *Enterococcus faecalis* strains isolated in Londrina, Brazil. *J Med Microbiol.* 2004;**53**(Pt 11):1069-73. doi: [10.1099/jmm.0.45654-0](https://doi.org/10.1099/jmm.0.45654-0). [PubMed: 15496382].